InvestSMART

Immuron Limited (ASX: IMC) - Announcements

- Current share price for IMC : $0.046

ASX company news and announcements for Immuron Limited (IMC) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Immuron Limited (IMC) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Immuron Limited (IMC), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Immuron Limited (IMC)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 Immuron FY2014 Travelan Sales Exceed $1m 7 Jul 2014 8:36AM $0.005 $0.046 risen by 820%
$15 Immuron Signs Agreement to Sell Travelan in South Korea 21 May 2014 9:59AM $0.005 $0.046 risen by 820%
$15 Immuron Extinguishes Paladin Debt 5 May 2014 9:48AM $0.005 $0.046 risen by 820%
$15 Appendix 4D and Interim Financial Report - Dec 2013 28 Feb 2014 8:25AM $0.008 $0.046 risen by 475%
$15 Renounceable Rights Issue - Closure, Acceptances & Shortfall 26 Feb 2014 9:53AM $0.005 $0.046 risen by 820%
$15 Immuron to Raise $9.66M via Fully Underwritten Rights Issue 22 Jan 2014 10:02AM $0.007 $0.046 risen by 557.14%
$15 Trading Halt 20 Jan 2014 9:28AM $0.011 $0.046 risen by 318.18%
$15 Immuron's Travelan Approved for Marketing in Canada 13 Nov 2013 9:53AM $0.012 $0.046 risen by 283.33%
$15 US FDA Clears Another IND for Phase 2 Trial for IMM-124E 8 Nov 2013 9:19AM $0.009 $0.046 risen by 411.11%
$15 Immuron Allowed Travelan Patent in the United States 23 Oct 2013 9:03AM $0.008 $0.046 risen by 475%
$15 Immuron to Adopt a New Direct-to-Wholesalers Sales Model 4 Jun 2013 10:32AM $0.004 $0.046 risen by 1,050%
$15 Prospectus -Underwritten Renounceable Rights Issue 27 Mar 2013 12:12PM $0.006 $0.046 risen by 666.67%
$15 Fully Underwritten Renounceable Rights Issue 27 Mar 2013 10:01AM $0.006 $0.046 risen by 666.67%
$15 Trading Halt 25 Mar 2013 9:03AM $0.008 $0.046 risen by 475%
$15 Further Positive Results on Clostridium Difficile Program 4 Mar 2013 10:05AM $0.009 $0.046 risen by 411.11%
$15 Half Year Results and Accounts 31 December 2012 28 Feb 2013 3:47PM $0.012 $0.046 risen by 283.33%
$15 Resignation of Joe Baini as Director and CEO. 22 Feb 2013 1:20PM $0.013 $0.046 risen by 253.85%
$15 CLOSTRIDIUM DIFFICILE Project Update 17 Dec 2012 9:54AM $0.008 $0.046 risen by 475%
$15 Positive Results from Colostridium Difficile Program 19 Sep 2012 9:46AM $0.017 $0.046 risen by 170.59%
$15 Travelan Distribution Agreement for China and Taiwan 12 Sep 2012 9:47AM $0.017 $0.046 risen by 170.59%
$15 Results for Announcement to the Market 31 Aug 2012 12:32PM $0.018 $0.046 risen by 155.56%
$15 Influenza program for Swine Flu 15 Aug 2012 8:48AM $0.018 $0.046 risen by 155.56%
$15 NIH Grant for Immuron's IMM 124E for Alcholic Fatty Liver 6 Aug 2012 10:05AM $0.016 $0.046 risen by 187.50%
$15 Prospectus for Bonus Issue of Options 9 Jul 2012 11:26AM $0.022 $0.046 risen by 109.09%
$15 Finalisation of Share Purchase Plan 18 Jun 2012 8:33AM $0.019 $0.046 risen by 142.11%

701 - 725 of 782 results

Page 29 of 32

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.